Translational pathology of neoplasia

Cancer Biomarkers

Volumn 9, Issue 1-6, 2011, Pages 7-20

  Grizzle, William E ^a   Srivastava, Sudhir ^b   Manne, Upender ^a  

^a University of Alabama at Birmingham   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

biomarkers; diagnosis; early detection; histopathology; imaging; individualized medical care; medical costs; molecular features; personalized medicine; prediction; prevalence; prevention; prognosis; receiver operating characteristic; risk assessment; Sensitivity; side effects; specificity; surrogate endpoints; treatment

Indexed keywords

ABARELIX; ALEMTUZUMAB; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; DASATINIB; DENILEUKIN DIFTITOX; DNA; ERLOTINIB; GEFITINIB; GEMTUZUMAB; IBRITUMOMAB TIUXETAN; IMATINIB; MESSENGER RNA; MYLOTARY; REPARIXIN; RITUXIMAB; SORAFENIB; SUNITINIB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; ZEVALEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DIAGNOSTIC ACCURACY; DRUG TARGETING; EARLY DIAGNOSIS; HUMAN; KIDNEY CANCER; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR IMAGING; MOLECULAR PATHOLOGY; MOUTH CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSLATIONAL PATHOLOGY; TREATMENT RESPONSE;

EARLY DETECTION OF CANCER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 82955193289     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0159     Document Type: Article

References (69)

1. W. E. Grizzle, R. B. Myers and U. Manne, TheUse of Biomarker Expression to Characterize Neoplastic Processes, Biotech Histochem 72(2) (1997), 96-104. PMID: 9152522.
2. R. B. Myers and W. E. Grizzle, Changes in Biomarker Expression in theDevelopment of Prostatic Adenocarcinoma, Biotech Histochem 72(2) (1997), 86-95. PMID: 9152521.
3. W. E. Grizzle, U. Manne, N. C. Jhala and H. L. Weiss, Molecular Characterization of Colorectal Neoplasia in Translational Research, Arch Pathol Lab Med 125(1) (2001), 91-98. PMID: 11151060.
4. C. Chatla, N. C. Jhala, V. R. Katkoori, D. Alexander, S. Meleth, W. E. Grizzle and U. Manne, Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma, Cancer Biomark 1 (2005), 241-250.
5. D. Alexander, N. Jhala, C. Chatla, J. Steinhauer, E. Funkhouser, C. S. Coffey, W. E. Grizzle and U. Manne, High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas, Cancer 103(10) (2005), 2163-2170.
6. C. J. Fabian, B. F. Kimler, J. Anderson, O. W. Tawfik, M. S. Mayo,W. E. Jr. Burak, J. A. O'Shaughnessy, K. S. Albain, D. M. Hyams, G. T. Budd, P. A. Ganz, E. R. Sauter, S. W. Beenken, W. E. Grizzle, J. P. Fruehauf, D. W. Arneson, J. W. Bacus, M. D. Lagios, K. A. Johnson and D. Browne, Breast cancer chemoprevention phase I evaluation of biomarker modulation by Arzoxifene, a third generation selective estrogen receptor modulator, Clin Can Research 10 (2004), 5403-5417.
7. H. Kim, D. E. Morgan, D. J. Buchsbaum, H. Zeng, W. E. Grizzle, J. M. Warram, C. R. Stockard, L. R. McNally, J. W. Long, J. C. Sellers, A. Forero and K. R. Zinn, Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusionweighted magnetic resonance imaging, Cancer Res 68(20) (2008), 8369-8376.
8. H. Kim, D. E. Morgan, H. Zeng, W. E. Grizzle, J. M. Warram, C. R. Stockard, D. Wang and K. R. Zinn, Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody, Radiology 248(3) (2008), 844-851.
9. L. I. Talley, W. E. Grizzle, J. W. Waterbor, K. Brown, H. Weiss and A. R. Frost, Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopasal women, Int J Cancer 98(1) (2002), 118-127.
10. L. Talley, D. C. Chhieng, W. C. Bell, W. E. Grizzle and A. R. Frost, Immunohistochemical detection of EGFR, p185 (erbB- 2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women, Biotech Histochem 83(1) (2008), 5-14.
11. N. Jhala, D. Jhala, S. M. Vickers, I. Eltoum, S. K. Batra, U. Manne, M. Eloubeidi, J. J. Jones and W. E. Grizzle, Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates: A model for translational research application, Am J Clin Pathol 126(4) (2006), 572-579.
12. D. J. Buschbaum, T. Zhou, W. E. Grizzle, P. G. Oliver, C. J. Hammond, M. Carpenter and A. F. LoBuglio, Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model, Clinical Cancer Res 9 (2003), 3731-3741.
13. R. D. Alvarez, M. G. Conner, H. Weiss, P. M. Klug, S. Niwas, U. Manne, J. Bacus, V. Kagan, K. C. Sexton, C. J. Grubbs, I. E. Eltoum and W. E. Grizzle, The efficacy of 9-cis retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplaia: Results of a randomized double blind clinical trial, Cancer Epidemiol Biomarkers Prev 12(2) (2003), 114-119.
14. D. J. Buschbaum, J. A. Bonner, W. E. Grizzle, M. A. Stackhouse, M. Capenter, D. J. Hicklin, P. Bohlen and K. P. Raisch, Treatment of pancreatic cancer xenografts with Erbitux (IMCC225) anti-EGFR antibody, gemcitabine, and radiation, Int J Radia Oncol Biol Phys 54(4), 1180-1193.
15. S. Beenken, Jr. R. Hockett,W. Grizzle, H. L. Weiss, A. Pickens, M. Perloff,W. F. Malone and K. I. Bland, Transforming growth factor a (TGF-a): A surrogate endpoint biomarker? J Am Coll Surg 195(2) (2002), 149-158. (Not found in PubMed).
16. W. E. Grizzle, U. Manne, H. L. Weiss, N. Jhala and L. I. Talley, Molecular staging of colorectal cancer in African-American nd Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 and p27kip-1, Int J Cancer 97(4) (2002), 403-409. PMID: 11802199.
17. D. Urban, W. Irwin, M. Kirk, M. A. Markiewicz, R. Myers, M. Smith, H. Weiss, W. E. Grizzle and S. Barnes, The Effect of Isolated Soy Protein on Plasma Biomarkers in Elderly Men with Elevated Serum Prostate Specific Antigen, J Urol 165 (2001), 294-300. PMID: 11125428.
18. R. B. Myers, D. K. Oelschlager, H. L. Weiss, A. R. Frost and W. E. Grizzle, Fatty Acid Synthase - An Early Molecular Marker of Progression of Prostatic Adenocarcinoma to Androgen Independence, J Urol, Investigative Urology 165(3) (2001), 1027-1032. PMID: 11176534.
19. U. Manne, H. Weiss and W. E. Grizzle, Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas, Clin Cancer Res 6(10) (2000), 4017-4025. PMID: 11051251.
20. U. Manne, H. L. Weiss and W. E. Grizzle, Bcl-2 Expression is Associated with Improved Prognosis in Patients with Distal olorectal Adenocarcinomas, Int J Cancer 89(5) (2000), 423-430. PMID: 11008204.
21. C. J. Piyathilake, A. R. Frost, U. Manne, W. C. Bell, H. Weiss, D. C. Heimburger and W. E. Grizzle, The Expression of Fatty Acid Synthease (FASE) is an Early Event in the Development and Progression of Squamous Cell Carcinoma of the Lung, Hum Pathol 31(9) (2000), 1068-1073. PMID: 11014573.
22. M. N. Saleh, K. P. Raisch, M. A. Stackhouse, W. E. Grizzle, J. A. Bonner, M. S. Mayo, H-G. Kim, R. F. Meredith, R. H. Wheeler and D. J. Buchsbaum, Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and Radiation, Cancer Biother Radiopharm 14(6) (1999), 451-463. (Not found in PubMed).
23. S. Beenken, M. Sellers, P. Huang, G. Peters, H. Krontiras, P. Dixon and C. Stockard, Listinsky C, Grizzle WE. Transforming Growth Factor a (TGFa), Expression in Dysplastic Oral Leukoplakia: Modulation by 13-cis Retinoic Acid, Head Neck 21(6) (1999), 566-573. PMID: 10449674.
24. D. Urban, R. Myers, U. Manne, H. Weiss, J. Mohler, D. Perkins, M. Marklewicz, R. Lieberman, G. Kelloff, M. Marshall and W. Grizzle, Evaluation of Biomarker Modulation by Fenreinide in Prostate Cancer Patients, Eur Urol 35(5-6) (1999), 429-438. PMID: 10325501.
25. B. E. Rogers, R. I. Garver, W. E. Grizzle and D. J. Buchsbaum, Genetic Induction of Antigens and Receptors as Targets for Cancer Radiotherapy, Tumor Targeting 3 (1998), 122-137. (Not found in PubMed).
26. M. N. Saleh, A. B. Tilden, R. F. Meredith, A. F. LoBuglio and W. E. Grizzle, Chimeric Antibodies with Specificity for Tumor Antigens: Demonstration of in situ Localization to Tumors after Antibody Therapy, Biotech Histochem 73(4) (1998), 186-197. PMID: 9888018.
27. C. J. Fabian, B. F. Kimler, R. M. Elledge, W. E. Grizzle, S. W. Beenken and J. H. Ward, Models for early chemoprevention trials in breast cancer, Hematol Oncol Clin North Am 12(5) (1998), 993-1017. PMID: 9874449.
28. U. Manne, H. L. Weiss, R. B. Myers, O. K. Danner, C. Moron, S. Srivastava and W. E. Grizzle, Nuclear Accumulation of p53 in Colorectal Adenocarcinoma: Prognostic Importance Differs with Race and Location of the Tumor, Cancer 83(12) (1998), 2456-2467. PMID: 9870854.
29. M. Kim, M. Wright, J. Deshane, M. A. Accavitti, A. Tilden, M. Saleh, W. P. Vaughan, M. H. Carabasi, M. D. Rogers, R. D. Hockett,W. E. Grizzle and D. T. Curiel, A Novel Gene Therapy Strategy for Elimination of Prostate Carcinoma Cells from Human Bone Marrow, Hum Gene Ther 8(2) (1997), 157-170. (Not found in PubMed).
30. D. Alexander, C. Chatla, E. Funkhouser, S. Meleth,W. E. Grizzle and U. Manne, Post-surgical disparity in survival between African-Americans and Caucasians with colonic adenocarcinomas, Clin Cancer Res 101(1) (2004), 66-76.
31. C. Rodriguez-Burford, M. N. Barnes, D. K. Oelschlager, R. B. Myers, L. I. Talley, E. E. Partridge andW. E. Grizzle, Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents, Clin Cancer Res 8(1) (2002), 202-209. PMID: 11801560.
32. W. E. Grizzle, S. Srivastava and U. Manne, The biology of incipient, pre-invasive or intraepithelial neoplasia, Cancer Biomark 9 (2011), 21-39.
33. R. Sankaranarayanan, B. M. Nene, S. S. Shastri et al. , HPV screening for cervical cancer in rural India, NEJM 360 (2009), 1385-1394.
34. G. D. Zimet, Improving adolescent health: focus on HPV vaccine acceptance, Journal of Adolescent Health 37(6) (2005), 517-523.
35. R. B. Myers, D. Brown, D. K. Oelschlager, J. W. Waterbor,M. E. Marshall, S. Srivastava, C. R. Stockard, D. A. Urban and W. E. Grizzle, Elevated Serum Levels of p105erbB-2 in Patients with Advanced Stage Prostatic Adenocarcinoma, Int J Cancer 69(5) (1996), 398-402. PMID: 8900374.
36. B. Hennessey, Jr. R. C. Bast, A. M. Gonzalez-Angulo and G. B. Mills, Early detection of cancer: molecular screening. In: The Molecular Basis of Cancer, (3rd ed. ), J. Mendelsohn, P. M. Howley, M. A. I rael, J. W. Gray and C. B. Thompson, eds, Philadelphia, PA:Saunders Elsevier, 2008, pp. 335-347.
37. I. M. Thompson, D. Pauler, P. J. Goodman, P. J. Tangen, M. S. Lucia, M. S. Parnes, L. M. Minasian, L. M. Ford, L. M. Lippman, E. D. Crawford, J. J. Crowley and Jr. C. A. Coltman, Prevalence of prostate cancer among men with a prostate-specific antigen level-ng per milliliter, NEJM 350(22) (2004), 2239-2246.
38. I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang, It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer, J Urol 180 (2008), 1219-1222.
39. W. E. Grizzle, O. J. Semmes, W. Bigbee, L. Zhu, G. Malik, G. Oelschlager, B. Manne and U. Manne, The need for the review and understanding of SELDI/MALDI mass spectroscopy data prior to analysis, Cancer Informatics 1(12005), 86-97.
40. D. M. Mellerik, M. Osborn and K. Weber, On the nature of serological tissue polypeptide antigen (TPA):monoclonal keratin 8, 18, 19 antibodies react differently with TPA prepared from human cultured carcinoma cells and TPA in human serum, Oncogene 5 (1990), 100-117.
41. R. Findeisen, S. Albrecht, B. Richter, K. Deutschmann andW. Distler, Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer, Clinical Chemistry and Laboratory Medicine 36(111998), 841-846.
42. A. S. Duffield and J. I. Epstein, Detection of cancer in radical prostatectomy specimens with no residual carcinoma in the initial review of slides, AJSP 33(12009), 120-125.
43. C. Sotiriou, C. Desmedt, V. Durbecq, L. Dal Lago, M. Lacroix, F. Cardoso and M. Piccart, Genomic and molecular classification of breast cancer. In: Molecular Oncology of Breast Cancer, J. S. Ross and G. N. Hortobagvi, eds, Sudbury, MA: Jones and Bartlett Publishers, 2005, pp. 81-95.
44. F. Bertucci, P. Finetti, N. Cervera, N. Charafe-Jauffret, E. Mamessier, J. Ad́eläide, S. Debono, G. Houvenaeghel, D. Maraninchi, P. Viens, C. Charpin, J. Jacquemier and D. Birnbaum, Gene expression of profiling shows medullary breast cancer is a subgroup of basal breast cancers, Cancer Res 6(92006), 4636-4644.
45. T. Sørlie, R. Tibshirani, J. Parker, T. Hastie, T. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Demeter, C. M. Perou, P. E. Lønning, P. O. Brown, A-L. Børresen-Dale and D. Botstein, Repeated observation of breast tumor subtypes in independent gene expression data sets, PNAS 100(142003), 8418-8423.
46. Z. Hongjuan, A. Langerød, J. Youngran, K. W. Nowels, J. M. Nesland, J. M. Tibshirani, I. K. Bukholm, R. Kårensen, D. Botstein, A-L. Børresen-Dale and S. S. Jeffrey, Different gene expression patterns in invasive lobular and ductal carcinomas of the breast, Mol Biol Cell 15 (2004), 2523-2536.
47. C. M. Perou, T. Sørlie,M. B. Elsen,M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. J. R. Pollack, Ross, H. Johnsen, L. A. Akslen, ø, Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lenning, A. -L. Børresen-Dale, P. O. Brown and D. Botstein, Molecular portraits of human breast tumours (letter), Nature 406 (2000), 747-752.
48. F. Bertucci, P. Finetti, N. Cervera, B. Esterni, F. Hermitte, P. Viens and D. Birnbaum, How basal are triple-negative breast cancers? Int J Cancer 123 (2008), 236-240.
49. L. K. Diaz, V. L. Cryns, W. F. Symmans and N. Sneige, Triple negative breast carcinoma and the basal phenotype: From expression profiling to clinical practice, Adv Anat Pathol 14 (2007), 419-430.
50. J. S. Reis-Filho and A. N. J. Tutt, Triple negative tumours: a critical review, Histopathology 52 (2008), 108-118.
51. S. Beenken, P. Huang, M. Sellers, G. Peters, G. Listinsky, C. Stockard,W. Hubbard, R. Wheeler andW. E. Grizzle, Retinoid Modulation of Biomarkers in Oral Leukoplakia/Dysplasia, Cell Biochem 19 (1994), 270-277. PMID: 7823600.
52. H. B. Burke, Outcome prediction and the future of the TNM staging system. (Editorial) Journal of the National Cancer Institute 96(192004), 1409.
53. N. Poulin, A. Frost, A. Carraro, E. Mommers, M. Guillaud, P. J. Van Diest, P. J. Grizzle and S. Beenken, Risk biomarker assessment for breast cancer progression: replication precision of nuclear morphometry, Anal Cell Pathol 25(32003), 129-138.
54. S. Varambally, S. M. Dhanasokaran, M. Zhou, T. R. Barrette, C. Kumar-Sinha, M. G. Sanda, D. Ghosh, K. J. Plenta, R. G. A. B. Sewall, A. P. Otte, M. A. Rubin and A. M. Chinnaiyan, The polycomb group protein EZH2 is involved in progression of prostate cancer.
55. D. F. Chhieng, A. R. Frost, L. L. Talley andW. E. Grizzle, Biology of Breast Cancer. Molecular and pathologic features of ductal neoplasia of the breast: Racial Considerations. In: Breast Cancer in Women of African Descent, C. K. O. Williams, C. P. Hunter, C. Falkson and O. Olopade, eds, Chapter 3, 2005, pp. 39-70. C. C. McIlwain, D. M. Townsend and K. D. Tew, Glutathione S-transferase polymorphisms: cancer incidence and therapy, Oncogene 25 (2006), 1639.
56. D. W. Hein, N-Acetyltransferase genetic and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis, Toxicol Lett (2000), 112-113, 349.
57. D. W. Hein, N-Acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk, Oncogene 25 (2006), 1649.
58. J. A. Bonner, D. J. Buchsbaum, B. E. Rogers, W. E. Grizzle, H. Q. Trummell, D. T. Curiel, J. B. Fiveash, R. Ove and K. P. Paisch, Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFR) enhances the radiosensitization properties of anti-EGFR treatment in prostate cancer cells, Int J Radiat Oncol Biol Phys 58(32004), 950-958.
59. M. Varella-Garcia, T. Mitsudomi, T. Yatabe, T. Kosaka, E. Nakajima, A. C. Xavier, M. Skokan, C. Zeng, W. A. Franklin, P. A. Jr. Bunn and F. R. Hirsch, EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery; impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort, J Thorac Oncol 4(32009), 318-325.
60. B. A. Helfrich, D. Raben, D. Varella-Garcia, D. Gustafson, D. Chan, D. Bernie, D. Coldren, D. Baron, D. Zeng, D. Franklin, D. Hirsch, A. Gazdar, J. Minna and P. A. Jr. Bunn, Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFRmutations but not EGFR protein levels, Clin Cancer Res 12(232006), 7117-7125.
61. K. R. Zinn, T. R. Chaudhuri, V. N. Krasnykh, D. J. Buschbaum, D. J. Belousova, D. J. Grizzle, D. J. Curiel and B. E. Rogers, Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice, Radiology 223(22002), 417-425.
62. K. R. Zinn, D. J. Buchsbaum, T. Chaudhuri, T. Mountz, T. Grizzle and B. E. Rogers, Noninvasive Monitoring of Gene Transfer Using a Reporter Receptor Imaged with a High Affinity Peptide Radiolabeled with 99mTc or 188Re, J NuclMed 41(52000), 887-895.
63. W. Grizzle, Special symposium: fixation and tissue processing models, Biotech Histochem 22 (Jun 2009), 1-9. NIHMSID: NIHMS116025.
64. M. M. Arnold, S. Srivastava, S. Fredenburgh, C. R. Stockard, C. R. Myers and W. E. Grizzle, Effect of Fixation and Tissue Processing on Immunohistochemical Demonstration of Specific Antigens, Biotech Histochem 71(51996), 224-230. PMID: 8896794.
65. D. Otali, C. Stockard, D. Oelschlager, D. Wan, D. Manne, D. Watts and W. E. Grizzle, The combined effects of formalin fixation and individual steps in tissue processing on immunorecognition, Biotech Histochem 26 (Jun 2009), 1-25.
66. C. R. Taylor, Standardization in immunohistochemistry: the role of antigen retrieval inmolecular morphology, Biotech and Histochem 81 (2006), 3-12
67. W. C. Bell, K. C. Sexton and W. E. Grizzle, Organizational issues in providing high-uality human tissues and clinical information for the support of biomedical research, in: Methods Mol Bilo, (Vol. 576), R. Grützmann and C. Pilarsky, eds, 2010, pp. 1-30.
68. A. Steg, W. Wang, C. Blanquicett, J. M. Grunda, I. A. Eltoum, K. Wang, K. Buchsbaum, K. Vickers, S. Russo, R. B. Diasio, A. R. Frost, W. E. Grizzle and M. R. Johnson, Multiple gene expression analyses in paraffin-embedded tissues by Taqman low density array: application to Hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma, J Mol Diagn 8(12006), 76-83.
69. A. Steg, A. Vickers, M. Eloubeidi, W. Wang, I. A. Eltoum, W. E. Grizzle, M. W. Saif, A. F. Lobuglio, A. R. Frost and M. R. Johnson, Hedgehog pathway expression in heterogeneous pancreatic adenocarcinoma: implications for the molecular analysis of clinically available biopsies, Diagn Mol Pathol 16(42007), 229-237.